Sponsors (8)
The bill aims to lower drug prices and increase transparency by allowing the government to label 'excessive' prices and force open licensing and reporting, but it trades off increased regulatory complexity, legal and administrative costs, and meaningful risks to pharmaceutical innovation and market behavior.
Patients (especially those with chronic conditions), insurers, and public payers are likely to pay lower prices for certain brand drugs because the bill enables HHS to find prices 'excessive' and forces or facilitates open, non‑exclusive licensing with capped royalties and AMP/WAC-based comparisons.
Faster market entry for generics and biosimilars (priority review, waived exclusivities, and clearer statutory definitions) should increase competition and speed patient access to lower‑cost alternatives.
Patients, taxpayers, and policymakers gain substantially more transparency — public postings, a searchable database, and detailed reporting on pricing determinations, licenses, revenues, R&D and clinical‑trial investments improve oversight and consumer decision‑making.
Drugmakers could reduce R&D investment, delay or limit U.S. launches, or withdraw products from the U.S. market in response to revenue loss or weakened exclusivities, risking fewer new therapies and slower medical innovation.
The bill creates substantial administrative, regulatory, and legal burdens for HHS, FDA, FTC, courts, and manufacturers (determinations, licensing, reporting, enforcement and litigation), which could produce backlogs, slow decisions, and raise implementation costs borne by taxpayers and providers.
Manufacturers face increased litigation risk, reputational harm, and large financial liabilities (repayment of revenue increases, large penalties, public listing) that could be imposed before appeals are resolved, potentially raising compliance costs that flow through to consumers or taxpayers.
Based on analysis of 8 sections of legislative text.
Creates a federal process to label brand drugs with excessive prices, void certain exclusivities, permit open licensing for competitors, require manufacturer reporting, and set royalty and enforcement rules.
Official title: Significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
Introduced May 20, 2025 by Bernard Sanders · Last progress May 20, 2025
Creates a federal process for identifying brand-name drugs with “excessive” U.S. prices, opens government-backed waivers of FDA exclusivities for drugs found excessive so competitors can make generics/biosimilars, and sets rules for royalties, reporting, enforcement, and public transparency. It requires annual manufacturer price data reporting, authorizes FDA to fast-track competing applications and to sue or recover revenues tied to unlawful post‑finding price increases, and directs FDA to publish a public database and annual reports. The bill replaces some market exclusivity rights for drugs deemed excessively priced, mandates reasonable royalties to original rights‑holders, prohibits coordinated anticompetitive conduct aimed at blocking the scheme, and imposes civil penalties on manufacturers that fail to report or provide false data. It sets timelines (30 days to start reviews; 8 months for prioritized review) and detailed factors for determining excessiveness, including international price comparisons, clinical value, R&D and federal subsidies, and revenue history.